Other languages Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:49 2024-05-08 am EDT			5-day change	1st Jan Change
2,003 ^DKK	-0.45%		+2.38%	-7.05%

May. 03	GENMAB : A good start to 2024; guidance unchanged
May. 03	Genmab Posts Q1 Net Profit Surge; Revenue Jumps	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OPINIONI DEGLI ANALISTI DEL GIORNO : Italgas, Amplifon, Enel, BBVA, Aperam, Safran, Santander, Pandora, Amadeus It, Lonza, ASM International...	May. 07
AVIS D'ANALYSTES DU JOUR : Thales, Safran, Schneider, Ubisoft, Pandora, Lonza, ASM International...	May. 07
OPINIONES DE LOS ANALISTAS DEL DÍA : ACS, Vidrala, Indra Sistemas, Enagás, BBVA, Santander, Pandora, Amadeus It, Lonza, ASM International...	May. 07
OPINIONI DEGLI ANALISTI DEL GIORNO : ACS, Safran, Santander, Endesa, Amadeus It, Telefónica, Aena, Cellnex, Sixt, JCDecaux...	May. 06
AVIS D'ANALYSTES DU JOUR : Crédit Agricole, Safran, Société Générale, Vinci, Air France, Cellnex, JCDecaux...	May. 06
OPINIONES DE LOS ANALISTAS DEL DÍA : ACS, Safran, Santander, Endesa, Amadeus It, Telefónica, Aena, Cellnex, Sixt, JCDecaux...	May. 06
GENMAB : A good start to 2024; guidance unchanged	May. 03
Aggiornamento sui forti movimenti della giornata: Banks, Genmab, Daimler Truck ... risultati riassunti qui!	May. 03
Actualización de las fuertes variaciones del día: Bancos, Genmab, Daimler Truck ... ¡resultados resumidos aquí!	May. 03
Les actions en mouvement : Les banques, JCDecaux, Bonduelle ... les publications de résultats résumées ici !	May. 03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	May. 02
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	May. 02
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	Apr. 30
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	Apr. 29
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29
AVIS D'ANALYSTES DU JOUR : BNP Paribas, Renault, Pernod-Ricard, Eurofins, Ferrari, Worldline, Sika, Elior...	Apr. 04
OPINIONES DE LOS ANALISTAS DEL DÍA : Adyen, Burberry, Endesa, Ferrari, Genmab, Melia Hotels, Telefónica, Sika..	Apr. 04
Genmab : l'acquisition de ProfoundBio accueillie sans émotion	Apr. 03
Genmab A/S Re-Affirms Revenue Guidance for the Year 2024	Apr. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT